Please check your internet connection and try again.
## Pantoprazole
### Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
### Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.
### Adult Dosing
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions:** Starting dose typically 40 mg orally twice daily, titrate to lowest effective dose. Doses up to 240 mg daily have been administered.
### Pediatric Dosing
* **12 years and older:**
* **Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Less than 12 years:** Dosing is not well-established for all indications. For GERD, 15-30 kg: 20 mg once daily; >30 kg: 40 mg once daily. Consult specific guidelines or literature for detailed pediatric dosing.
### Dose Adjustments
No dose adjustment necessary for renal or hepatic impairment, though caution is advised in severe hepatic impairment.
### Contraindications
Hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
### Adverse Effects
Common: Headache, diarrhea, nausea, abdominal pain, dizziness, flatulence.
Serious: Bone fracture risk (hip, wrist, spine) with prolonged use, *Clostridium difficile*-associated diarrhea, hypomagnesemia, vitamin B12 deficiency.
### Key Drug Interactions
* **Drugs Dependent on Gastric pH for Absorption:** Absorption may be decreased (e.g., ketoconazole, itraconazole, iron salts, mycophenolate mofetil).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19; potential for increased concentrations of drugs metabolized by this enzyme (e.g., clopidogrel, although clinical significance is debated).
### Monitoring
* Magnesium levels periodically, especially with long-term use (>1 year) or concurrent diuretic use.
* Bone mineral density in patients at risk for osteoporosis.
* Symptoms of B12 deficiency with long-term therapy.
* Monitor for *C. difficile* infection.
### Clinical Pearls
* Administer 30-60 minutes before a meal.
* For delayed-release tablets, do not crush, chew, or split.
* Long-term PPI use is associated with increased risk of fractures, *C. difficile* infection, hypomagnesemia, and vitamin B12 deficiency. Use the lowest effective dose for the shortest duration needed.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
